Mothaffar Rimawi, MD
Enriched profileProfessor, Department of Medicine, Section of Hematology and Oncology, Baylor College of Medicine; Dan L Duncan Professor of Medicine · Baylor College of Medicine
Mothaffar Rimawi is Professor, Department of Medicine, Section of Hematology and Oncology, Baylor College of Medicine; Dan L Duncan Professor of Medicine at Baylor College of Medicine. OpenAlex indexes 549 publications with 10,847 citations (h-index 56); ClinicalTrials.gov lists 21 registered studies with this person as an investigator.
Data verified 14 Oct 2026
Overview
Updated 16 Oct 2026
Mothaffar Rimawi, M.D., is Professor, Department of Medicine, Section of Hematology and Oncology, Baylor College of Medicine. The public record shows 549 publications with 10,847 citations (h-index 56), centered on Breast Cancer Treatment Studies, HER2/EGFR in Cancer Research, Gastric Cancer Management and Outcomes. It also documents an investigator role on 21 registered clinical trials, industry payments reported by 17 companies, 3 NIH-funded awards (2010–2023).
- Most recent indexed publication: 2026 · Clinical pharmacology and therapeutics
- Top research focus: Breast Cancer Treatment Studies
- 21 registered trials on ClinicalTrials.gov
- Open Payments reporting from 17 companies
Generated from the cited public record · current as of 16 Oct 2026. Every fact links its source below.
Indications focus
from trials led + research topicsResearch focus
OpenAlex concept fingerprintDrugs & molecules
across trials, industry payments and publicationsWorks with
trial sponsors and companies reporting paymentsScholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID; 24 in PubMed.
Total citations across indexed works.
Hirsch index (OpenAlex). i10-index 119.
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Telephone
Practice address and telephone from the federal NPPES registry.
Sign in to view contact details →Clinical trials
Updated 16 Oct 2026
Listed as an investigator on 21 registered studies on ClinicalTrials.gov. The most recent:
- A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence
Sponsor: Stemline Therapeutics, Inc.
- Phase 3 Study to Evaluate the Efficacy and Safety of HER2/Neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/Neu Positive Subjects
Sponsor: Greenwich LifeSciences, Inc.
- Correlation of Clinical Response to Pathologic Response in Patients With Early Breast Cancer
Sponsor: Baylor Breast Care Center
Industry payments
Updated 16 Oct 2026
17 companies reported payments to CMS in program years 2021–2025. These are public disclosures, not judgments. The latest:
- AstraZeneca UK LimitedProgram year20256 payments
- Daiichi Sankyo Inc.Program year20253 payments
- Genentech USA, Inc.Program year20252 payments
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
100%Aromatase Inhibitor100%Letrozole100%Part D≥15 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
Updated 16 Oct 2026
3 NIH research awards on record, funded 2010–2023 per NIH RePORTER. The latest:
- Translational Breast Cancer Research Training Program
Baylor College of Medicine
FY2022$193,635T32CA203690 - Translational Breast Cancer Research Training Program
Baylor College of Medicine
FY2021$207,275T32CA203690
Congress activity
Updated 16 Oct 2026
153 congress contributions (2006–2026) across AACR, ASCO, ESMO, SABCS per OpenAlex. The most recent:
- Abstract 6647: MCM2 and the origin licensing complex: A putative node of ER+/HER2- breast cancer therapy resistance.
AACR Annual Meeting
AACR2026Co-author
Published abstracts are attributed via the same ORCID-disambiguated authorship as publications, so each is DOI-verified. Podium roles (invited talks, session chairs) and oral/poster type are added as program data is confirmed.
Publications
Updated 16 Oct 2026
Their five most recent publications, matched to their ORCID record and linked to PubMed.
- Systematic Evaluation of Data and Trial Fitness for Oncology Trial Emulation: Empirical Findings from the CARE Initiative.
Clinical pharmacology and therapeutics
Article2026 - Prognostic value of visually and computationally assessed tumor-infiltrating lymphocytes in early-stage triple-negative breast cancer (TBCRC-030).
Journal of the National Cancer Institute
Clinical Trial2026
Most-cited works
by citation count (OpenAlex)- 01
- 02
- 03
- 04
- 05Towards personalized treatment for early stage HER2-positive breast cancerReview287 citations2019
Network
Updated 16 Oct 2026
The people this person publishes with most, by number of co-authored papers. Names link to their own profile when we have one.
Online presence
Updated 16 Oct 2026
This person's own public accounts first, then places where others mention them. Two different things, listed separately.
Owned accounts
public accounts run by this person- Doximity
doximity.com/pub/mothaffar-rimawi-md
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →doximity.com ↗ - Other
profiles.viictr.org/profile/269416
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →profiles.viictr.org ↗
Mentions by others
where others cite or feature them- Other
hamad.qa/EN/All-Events/ABCC2021/Speakers/Pages/Mothaffar-F-Rimawi.aspx
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →hamad.qa ↗ - Other
hamad.qa/EN/All-Events/ABCC2023/Speakers/Pages/Mothaffar-F-Rimawi.aspx
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →hamad.qa ↗ - Other
celcuity.com/team/mothaffar-f-rimawi-md
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →celcuity.com ↗ - Other
emedevents.com/speaker-profile/mothaffar-fahed-rimawi
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →emedevents.com ↗
We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.
Background & recognition
Updated 16 Oct 2026
Credentials, appointments and honors, newest first, each linked to the public source it came from.
Education
degrees and training on recordEditorial & leadership roles
journal and society appointments- Vice Chair
Breast Committee, NRG Oncology Group
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →hamad.qa ↗ - Co-Chair
HER2 Working Group, Translational Breast Cancer Research Consortium (TBCRC)
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →hamad.qa ↗ - Member
American College of Physicians
- Member
American Society of Clinical Oncology (ASCO)
- Member
American Association for Cancer Research (AACR)
Awards & honors
honors on the public record- Board Certified in Internal Medicine
American Board of Internal Medicine
- Board Certified in Medical Oncology
American Board of Internal Medicine
Secondary affiliations
appointments beyond the home institution- Executive Medical Director and Associate Director for Clinical Affairs
Dan L Duncan Comprehensive Cancer Center
- Philip A. Salem
M.D. Chair in Cancer Research, Baylor St. Luke's Medical Center
- Director of Clinical Research
Lester and Sue Smith Breast Center
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →celcuity.com ↗
Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.
Similar KOLs
Other experts from the same institution or the same specialty.
Christie Ballantyne, MD
Baylor College of Medicine
Biykem Bozkurt, MD
Baylor College of Medicine
Garabed Eknoyan, MD
Baylor College of Medicine
Sankar Navaneethan, MD
Baylor College of Medicine
Gabriel Hortobagyi, MD
The University of Texas MD Anderson Cancer Center
Eric Winer, MD
Yale School of Medicine
Hope Rugo, MD
City of Hope
Dennis Slamon, MD
University of California, Los Angeles